Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 150Telomeres, Telomerase, and SenescenceRetinal Diseases and TreatmentsRetinal Development and Disorders

The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.

Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration

Open access

Abstract

Age-related macular degeneration (AMD), a degenerative disease in the central macula area of the neuroretina and the supporting retinal pigment epithelium, is the most common cause of vision loss in the elderly. Although advances have been made, treatment to prevent the progressive degeneration is lacking. Besides the association of innate immune pathway genes with AMD susceptibility, environmental stress- and cellular senescence-induced alterations in pathways such as metabolic functions and inflammatory responses are also implicated in the pathophysiology of AMD. Cellular senescence is an adaptive cell process in response to noxious stimuli in both mitotic and postmitotic cells, activated by tumor suppressor proteins and prosecuted via an inflammatory secretome. In addition to physiological roles in embryogenesis and tissue regeneration, cellular senescence is augmented with age and contributes to a variety of age-related chronic conditions. Accumulation of senescent cells accompanied by an impairment in the immune-mediated elimination mechanisms results in increased frequency of senescent cells, termed “chronic” senescence. Age-associated senescent cells exhibit abnormal metabolism, increased generation of reactive oxygen species, and a heightened senescence-associated secretory phenotype that nurture a proinflammatory milieu detrimental to neighboring cells. Senescent changes in various retinal and choroidal tissue cells including the retinal pigment epithelium, microglia, neurons, and endothelial cells, contemporaneous with systemic immune aging in both innate and adaptive cells, have emerged as important contributors to the onset and development of AMD. The repertoire of senotherapeutic strategies such as senolytics, senomorphics, cell cycle regulation, and restoring cell homeostasis targeted both at tissue and systemic levels is expanding with the potential to treat a spectrum of age-related diseases, including AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-021-02088-0

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Etiology and consequences of cellular senescence contributing to AMD. Cellular senescence is highly relevant to AMD pathogenesis. A variety of factors—telomere dysfunction, oxidative stress, nutrient signals, DNA damage, and inflammatory cytokines—can activate cellular senescence in both mitotic and post-mitotic cells. Senescent cells display altered metabolic function and autophagy activity, as well as a distinctive proinflammatory secretome, which are all interlinked. These processes directly impose a cause-and-effect on one another, further accelerating their progression. The consequences of chronic cellular senescence, such as increased drusen deposition, increased RPE, choriocapillaris and photoreceptor dysfunction and cell loss, and/or neovascularization, ultimately lead to the advanced disease phenotype of macular degeneration
Fig. 1 Etiology and consequences of cellular senescence contributing to AMD. Cellular senescence is highly relevant to AMD pathogenesis. A variety of factors—telomere dysfunction, oxidative stress, nutrient signals, DNA damage, and inflammatory cytokines—can activate cellular senescence in both mitotic and post-mitotic cells. Senescent cells display altered metabolic function and autophagy activity, as well as a distinctive proinflammatory secretome, which are all interlinked. These processes directly impose a cause-and-effect on one another, further accelerating their progression. The consequences of chronic cellular senescence, such as increased drusen deposition, increased RPE, choriocapillaris and photoreceptor dysfunction and cell loss, and/or neovascularization, ultimately lead to the advanced disease phenotype of macular degenerationCC BY · PubMed Central
Fig 2 A schematic diagram of consequences of the senescent retina and induction of SASP during progression of AMD. A healthy retina is an immune-privileged ocular tissue, with active immune regulatory networks and immune cell networks supporting normal retinal cell morphology and function [1, 7]. In contrast, a “senescent” retina has both damaged cells and impaired function with alterations in microglial morphology, migration, and infiltration of systemic immune cells. Additionally, resident neuronal cells (ganglion cells, horizontal cells, amacrine cells, and photoreceptors), RPEs, and microglia/macrophages, enter a senescent state in the senescent retina. Drusen begin to accumulate between the Bruch’s membrane and RPE or in the subretinal space (subretinal drusenoid deposits). The Bruch’s membrane thickens and choriocapillaris has a reduced vascular network alongside thinning and diminishing vessels in the aging choroid. Numerous SASP factors, such as IL-6, IL-12, TNF-α, IFN-γ, and IL-8, are released from the senescent retinal cells. ROS, in tandem with damaged DNA, further promote the age-related decline in RPE and photoreceptors resulting in a feedforward cycle of damage. Signaled by the SASP-chemokines released into the tissue environment, immune cells (monocytes, neutrophils, and T cells) extravasate from the blood vessels, infiltrate the retina, and release SASP components, contributing to a chronic inflammation and other AMD-related pathologies
Fig 2 A schematic diagram of consequences of the senescent retina and induction of SASP during progression of AMD. A healthy retina is an immune-privileged ocular tissue, with active immune regulatory networks and immune cell networks supporting normal retinal cell morphology and function [1, 7]. In contrast, a “senescent” retina has both damaged cells and impaired function with alterations in microglial morphology, migration, and infiltration of systemic immune cells. Additionally, resident neuronal cells (ganglion cells, horizontal cells, amacrine cells, and photoreceptors), RPEs, and microglia/macrophages, enter a senescent state in the senescent retina. Drusen begin to accumulate between the Bruch’s membrane and RPE or in the subretinal space (subretinal drusenoid deposits). The Bruch’s membrane thickens and choriocapillaris has a reduced vascular network alongside thinning and diminishing vessels in the aging choroid. Numerous SASP factors, such as IL-6, IL-12, TNF-α, IFN-γ, and IL-8, are released from the senescent retinal cells. ROS, in tandem with damaged DNA, further promote the age-related decline in RPE and photoreceptors resulting in a feedforward cycle of damage. Signaled by the SASP-chemokines released into the tissue environment, immune cells (monocytes, neutrophils, and T cells) extravasate from the blood vessels, infiltrate the retina, and release SASP components, contributing to a chronic inflammation and other AMD-related pathologiesCC BY · PubMed Central
Fig. 3 Prospective senotherapeutic strategies to subvert AMD progression. (1) Selective elimination or modulation of senescent cells through senolytics such as dasatinib + quercetin, inhibitors of Bcl-2 or BET proteins, chimeric antigen receptor (CAR) T cells, or by modulating neutrophil-induced NETosis, which can redirect immune responses against senescent cells. (2) Modulation of senescence-related signaling networks (senomorphics) to attenuate SASP through, for example, regulating NF-κB, mTOR, and AMPK pathways, or utilizing monoclonal antibodies against SASP factors, such as IL-6. (3) Inhibition of senescence in the eye using cell cycle regulators, p53/Rb sumoylation inhibitors, mitochondria-derived peptides, or lipid mediators. (4) Restoration of cholesterol homeostasis/flux and normal function of macrophages via liver X receptor (LXR) agonists or miR-33 inhibition, which has proved beneficial in the inhibition of retinal degeneration in vivo
Fig. 3 Prospective senotherapeutic strategies to subvert AMD progression. (1) Selective elimination or modulation of senescent cells through senolytics such as dasatinib + quercetin, inhibitors of Bcl-2 or BET proteins, chimeric antigen receptor (CAR) T cells, or by modulating neutrophil-induced NETosis, which can redirect immune responses against senescent cells. (2) Modulation of senescence-related signaling networks (senomorphics) to attenuate SASP through, for example, regulating NF-κB, mTOR, and AMPK pathways, or utilizing monoclonal antibodies against SASP factors, such as IL-6. (3) Inhibition of senescence in the eye using cell cycle regulators, p53/Rb sumoylation inhibitors, mitochondria-derived peptides, or lipid mediators. (4) Restoration of cholesterol homeostasis/flux and normal function of macrophages via liver X receptor (LXR) agonists or miR-33 inhibition, which has proved beneficial in the inhibition of retinal degeneration in vivoCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 183 references

Cited by

See all 150

Metadata

Authors
Lee, K. S., Lin, S., Copland, D. A., Dick, A. D., & Liu, J.
Affiliations
  • University of Bristol (GB)
  • National Institute for Health and Care Research (GB)
Corresponding author
  • Dick, Andrew D.
  • Liu, Jian
Venue
Journal of Neuroinflammation
Published
2021-01-22
Volume
18
Issue
1
Pages
32-32
ISSN
1742-2094 (ISSN-L)
OpenAlex
W3123063922
Cited by
150
References
183
Citations by year
2026: 22 · 2025: 33 · 2024: 37 · 2023: 26 · 2022: 20 · 2021: 12
FWCI
3.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Bristol Research (University of Bristol) (publishedVersion, cc-by)
  • Explore Bristol Research (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Rosetrees Trust (M418-F1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
cellular senescence, age-related macular degeneration, senotherapy, senolytics, senomorphics, retinal pigment epithelium, retinal aging, senescence-associated secretory phenotype, chronic inflammation, immunosenescence, microglia, choroid, cell cycle regulation, reactive oxygen species
MeSH terms
Aging, Animals, Humans, Macular Degeneration, Retina, Cellular Senescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. https://app.cochat.ai/papers/10.1186/s12974-021-02088-0
The paper
Lee, K. S., Lin, S., Copland, D. A., Dick, A. D., & Liu, J. (2021). Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-021-02088-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.